DEFA14A: Onconetix Faces Nasdaq Compliance Hurdles, Proposes Reverse Stock Split to Maintain Listing

Onconetix is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq listing requirements after receiving notices regarding minimum bid price and stockholders' equity.

Summary

• Onconetix, Inc. is supplementing its definitive proxy statement due to a letter from Nasdaq regarding compliance with listing rules.
• Nasdaq determined that Onconetix's acquisition of Proteomedix AG constitutes a business combination resulting in a change of control, requiring the company to meet initial listing criteria, including a minimum share price of $4.00.
• The company is seeking stockholder approval for a reverse stock split, with a ratio ranging from 1-for-30 to 1-for-60, to increase its stock price and regain compliance with Nasdaq's minimum bid price rule of $1.00.
• Onconetix previously received a notice from Nasdaq on September 18, 2023, for not maintaining the minimum bid price of $1.00 per share.
• The company was granted an extension until September 16, 2024, to regain compliance with the bid price rule.
• On May 8, 2024, Onconetix received another notice for not meeting the minimum stockholders' equity requirement of $2,500,000.
• Nasdaq granted an extension until November 4, 2024, to regain compliance with the minimum stockholders' equity requirement.
• Failure to comply with Nasdaq's listing rules could result in delisting, leading to reduced liquidity, analyst coverage, and access to capital.
• The company intends to release a portion of the Exchange Shares and the Conversion Shares from the Lock-Up Agreement and to effect the Reverse Stock Split to assist with satisfying applicable listing standards.
• The Board believes that the failure of stockholders to approve the Reverse Stock Split Amendment could prevent the Company from complying with the Bid Price Rule and the Minimum Price Rule and could, among other risks, inhibit our ability to conduct capital raising activities.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's non-compliance with Nasdaq listing rules and the potential for delisting. The proposed reverse stock split is a reactive measure, and its success is uncertain.

Positives

• Nasdaq granted Onconetix an extension until November 4, 2024, to regain compliance with the minimum stockholders' equity requirement.
• The company is taking proactive steps, such as proposing a reverse stock split, to address Nasdaq's compliance concerns.
• Onconetix intends to release a portion of the Exchange Shares and the Conversion Shares from the Lock-Up Agreement and to effect the Reverse Stock Split to assist with satisfying applicable listing standards.

Negatives

• Onconetix received notices from Nasdaq for not complying with the minimum bid price and stockholders' equity requirements.
• The company's stockholders' equity was reported as $1,404,476 for the fiscal year ended December 31, 2023, which is below the required $2,500,000.
• Failure to regain compliance with Nasdaq's listing rules could result in delisting, which would have material adverse consequences.

Risks

• Failure to obtain stockholder approval for the reverse stock split could hinder the company's ability to comply with Nasdaq's listing rules.
• Delisting from Nasdaq could significantly reduce the liquidity and trading volume of the company's common stock.
• The company's ability to maintain and obtain analyst coverage, attract investor interest, and access capital may be diminished if delisted.
• There is no assurance that the company will be able to comply with the applicable listing standards of Nasdaq.

Future Outlook

The company is focused on regaining compliance with Nasdaq listing requirements through a reverse stock split and other measures. Failure to do so could result in delisting and adverse consequences.

Industry Context

Many small-cap companies face challenges in maintaining Nasdaq listing compliance, especially regarding minimum bid price and stockholders' equity. Reverse stock splits are a common strategy to address these issues, but their success depends on various market factors and investor sentiment.

Comparison to Industry Standards

• Companies like [Comparable Company 1] and [Comparable Company 2] have also faced Nasdaq compliance issues and implemented reverse stock splits to regain compliance.
• The typical reverse stock split ratio ranges from 1-for-2 to 1-for-10, but Onconetix is considering a more aggressive range of 1-for-30 to 1-for-60, indicating the severity of their compliance challenges.
• The success of a reverse stock split depends on the company's ability to improve its financial performance and investor confidence after the split.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment value if the reverse stock split is not successful.
• Employees may be affected by the company's financial instability and potential delisting.
• The company's ability to attract and retain customers and suppliers may be impacted by its Nasdaq compliance issues.
• Creditors may be concerned about the company's ability to repay its debts if delisted.

Next Steps

• Stockholder vote on the reverse stock split proposal at the Annual Meeting on September 5, 2024.
• Implementation of the reverse stock split, if approved, at a ratio determined by the Board.
• Efforts to regain compliance with Nasdaq's minimum bid price and stockholders' equity requirements by September 16, 2024, and November 4, 2024, respectively.

Key Dates

Keywords

Nasdaq, compliance, reverse stock split, listing rules, minimum bid price, stockholders' equity, delisting, Onconetix, Proteomedix, acquisition